Zelig Eshhar

13.9k total citations · 3 hit papers
178 papers, 11.0k citations indexed

About

Zelig Eshhar is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, Zelig Eshhar has authored 178 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Radiology, Nuclear Medicine and Imaging, 85 papers in Immunology and 70 papers in Molecular Biology. Recurrent topics in Zelig Eshhar's work include Monoclonal and Polyclonal Antibodies Research (96 papers), CAR-T cell therapy research (59 papers) and T-cell and B-cell Immunology (34 papers). Zelig Eshhar is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (96 papers), CAR-T cell therapy research (59 papers) and T-cell and B-cell Immunology (34 papers). Zelig Eshhar collaborates with scholars based in Israel, United States and France. Zelig Eshhar's co-authors include Tova Waks, G. Gross, Daniel Schindler, Steven A. Rosenberg, Gideon Gross, James C. Yang, Patrick Hwu, Eran Elinav, Michal Baniyash and Silvana Canevari and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Zelig Eshhar

177 papers receiving 10.6k citations

Hit Papers

Specific activation and targeting of cytotoxic lymphocyte... 1989 2026 2001 2013 1993 1989 2006 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
    1993 1.2k citations Zelig Eshhar, Tova Waks et al. profile →
  2. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
    1989 1.2k citations Tova Waks, Zelig Eshhar et al. profile →
  3. A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
    2006 984 citations Zelig Eshhar et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zelig Eshhar Israel 53 6.6k 4.7k 3.7k 2.4k 2.2k 178 11.0k
Winfried S. Wels Germany 51 5.9k 0.9× 5.0k 1.1× 2.7k 0.7× 1.7k 0.7× 1.6k 0.7× 176 8.9k
Michael H. Kershaw Australia 50 7.6k 1.1× 6.4k 1.4× 2.8k 0.7× 522 0.2× 2.0k 0.9× 132 11.0k
Phillip K. Darcy Australia 65 9.2k 1.4× 7.5k 1.6× 3.9k 1.1× 600 0.2× 1.7k 0.8× 194 14.2k
Catia Traversari Italy 46 5.5k 0.8× 8.3k 1.8× 5.5k 1.5× 833 0.3× 2.2k 1.0× 109 12.7k
Hinrich Abken Germany 58 8.0k 1.2× 4.7k 1.0× 2.8k 0.8× 566 0.2× 2.4k 1.1× 219 10.2k
John R. Wunderlich United States 54 15.8k 2.4× 14.8k 3.2× 4.8k 1.3× 1.4k 0.6× 3.4k 1.6× 121 21.1k
Andrew Raubitschek United States 53 4.3k 0.7× 2.2k 0.5× 2.7k 0.7× 4.3k 1.8× 974 0.4× 157 9.1k
Zhiya Yu United States 54 8.8k 1.3× 8.6k 1.8× 3.9k 1.0× 469 0.2× 2.4k 1.1× 95 14.2k
Laurence J.N. Cooper United States 56 7.7k 1.2× 4.7k 1.0× 4.3k 1.1× 549 0.2× 3.0k 1.4× 236 11.4k
Claudio Bordignon Italy 58 5.9k 0.9× 5.0k 1.1× 5.9k 1.6× 366 0.2× 4.7k 2.2× 222 14.1k

Countries citing papers authored by Zelig Eshhar

Since Specialization
Citations

This map shows the geographic impact of Zelig Eshhar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zelig Eshhar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zelig Eshhar more than expected).

Fields of papers citing papers by Zelig Eshhar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zelig Eshhar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zelig Eshhar. The network helps show where Zelig Eshhar may publish in the future.

Co-authorship network of co-authors of Zelig Eshhar

This figure shows the co-authorship network connecting the top 25 collaborators of Zelig Eshhar. A scholar is included among the top collaborators of Zelig Eshhar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zelig Eshhar. Zelig Eshhar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rousso-Noori, Liat, Tova Waks, Anat Globerson Levin, et al.. (2021). P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas. Nature Communications. 12(1). 3615–3615. 31 indexed citations
2.
3.
Servais, Charlotte, Tova Waks, Markus Chmielewski, et al.. (2012). Redirected T Cells That Target Pancreatic Adenocarcinoma Antigens Eliminate Tumors and Metastases in Mice. Gastroenterology. 143(5). 1375–1384.e5. 86 indexed citations
4.
Artzy‐Schnirman, Arbel, R. Brener, Tova Waks, et al.. (2012). Mixed Alkanethiol Monolayers on Submicrometric Gold Patterns: A Controlled Platform for Studying Cell–Ligand Interactions. Nano Letters. 12(9). 4992–4996. 11 indexed citations
5.
Elinav, Eran, et al.. (2009). Amelioration of Colitis by Genetically Engineered Murine Regulatory T Cells Redirected by Antigen-Specific Chimeric Receptor. Gastroenterology. 136(5). 1721–1731. 143 indexed citations
6.
Agemy, Lilach, Alon Harmelin, Tova Waks, et al.. (2008). Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts. The Prostate. 68(5). 530–539. 15 indexed citations
7.
Pinthus, Jehonathan H., Tova Waks, Keren Kaufman‐Francis, et al.. (2004). Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. Journal of Clinical Investigation. 114(12). 1774–1781. 50 indexed citations
8.
Pinthus, Jehonathan H., Tova Waks, Keren Kaufman‐Francis, et al.. (2004). Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. Journal of Clinical Investigation. 114(12). 1774–1781. 57 indexed citations
9.
Pinthus, Jehonathan H., Tova Waks, Keren Kaufman‐Francis, et al.. (2003). Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.. PubMed. 63(10). 2470–6. 62 indexed citations
10.
Mabjeesh, Nicola J., Sharon Biton, Sharon Engel, et al.. (2002). Unusual Alternative Splicing within the Human Kallikrein Genes KLK2 and KLK3 Gives Rise to Novel Prostate-specific Proteins. Journal of Biological Chemistry. 277(20). 18084–18090. 50 indexed citations
11.
Lindner, Ariel B., et al.. (1997). Efficient and Selective P‐nitrophenyl‐ester‐hydrolyzing Antibodies Elicited by a P‐nitrobenzyl Phosphonate Hapten. European Journal of Biochemistry. 244(2). 619–626. 15 indexed citations
12.
Eshhar, Zelig, Cheryl Fitzer‐Attas, G Grosse, et al.. (1996). The T-body approach: potential for cancer immunotherapy. Springer Seminars in Immunopathology. 18(2). 199–209. 73 indexed citations
13.
Waks, Tova, et al.. (1994). Functional expression in mast cells of chimeric receptors with antibody specificity. Cell Biophysics. 24-25(1-3). 229–236. 7 indexed citations
14.
Tawfik, Dan S., Zelig Eshhar, & Bernard S. Green. (1994). Catalytic antibodies: A critical assessment. Molecular Biotechnology. 1(1). 87–103. 19 indexed citations
15.
Stancovski, Ilana, Daniel Schindler, Tova Waks, et al.. (1993). Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.. The Journal of Immunology. 151(11). 6577–6582. 169 indexed citations
16.
Nissim, Ahuva, et al.. (1993). Fine specificity of the IgE interaction with the low and high affinity Fc receptor. The Journal of Immunology. 150(4). 1365–1374. 35 indexed citations
17.
Nissim, Ahuva & Zelig Eshhar. (1992). The human mast cell receptor binding site maps to the third constant domain of immunoglobulin E. Molecular Immunology. 29(9). 1065–1072. 14 indexed citations
18.
Novick, Daniela, et al.. (1989). Monoclonal Antibodies to the Human Interferon-γ Receptor: Blocking of the Biological Activities of Interferon-γ and Purification of the Receptor. Journal of Interferon Research. 9(3). 315–328. 17 indexed citations
19.
Novick, Daniela, Zelig Eshhar, Michel Revel, & Y Mory. (1989). Monoclonal Antibodies for Affinity Purification of IL-6/IFN-β 2 and for Neutralization of HGF Activity. Hybridoma. 8(5). 561–567. 18 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Winfried S. Wels Breakdown of academic impact, for papers by Michael H. Kershaw Breakdown of academic impact, for papers by Phillip K. Darcy Breakdown of academic impact, for papers by Catia Traversari Breakdown of academic impact, for papers by Hinrich Abken Breakdown of academic impact, for papers by John R. Wunderlich Breakdown of academic impact, for papers by Andrew Raubitschek Breakdown of academic impact, for papers by Zhiya Yu Breakdown of academic impact, for papers by Laurence J.N. Cooper Breakdown of academic impact, for papers by Claudio Bordignon
Rankless by CCL
2026